• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. 
    •   QMRO Home
    • Blizard Institute
    • Centre for Primary Care and Public Health
    • Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
    •   QMRO Home
    • Blizard Institute
    • Centre for Primary Care and Public Health
    • Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.

    Volume
    35
    Pagination
    493 - 498
    DOI
    10.1016/j.eimc.2016.02.029
    Journal
    Enferm Infecc Microbiol Clin
    Issue
    8
    Metadata
    Show full item record
    Abstract
    INTRODUCTION: Limited data is available regarding the hepatic safety of maraviroc in patients co-infected with HIV and HCV and/or HBV. Our objective was to compare the hepatic safety profile and fibrosis progression in HIV-mono-infected patients and co-infected with HCV and/or HBV treated with maraviroc. METHODS: Retrospective multicentre cohort study of HIV-infected patients receiving treatment with a maraviroc-containing regimen in 27 hospitals in Spain. RESULTS: A total of 667 patients were analyzed, of whom 313 were co-infected with HCV (n=282), HBV (n=14), or both (n=17). Maraviroc main indications were salvage therapy (52%) and drug toxicity (20%). Grade 3-4 hypertransaminasaemia (AST/ALT >5 times ULN) per 100 patient-years of maraviroc exposure, was 5.84 (95% CI, 4.04-8.16) and 1.23 (95% CI, 0.56-2.33) in co-infected and HIV-mono-infected patients, respectively (incidence rate ratio, 4.77; 95% CI, 2.35-10.5). However, the degree of aminotransferase abnormalities remained stable throughout the study in both groups, and no significant between-group differences were seen in the cumulative proportion of patients showing an increase in AST/ALT levels greater than 3.5 times baseline levels. No between-group differences were seen in liver fibrosis over time. With a maraviroc median exposure of 20 months (IQR, 12-41), two patients (0.3%) discontinued maraviroc because of grade 4 hepatitis, and other 2 died due to complications associated to end-stage-liver disease. CONCLUSIONS: Maraviroc-containing regimens showed a low incidence of hepatitis in a large Spanish cohort of HIV-infected patients, including more than 300 patients co-infected with HCV and/or HBV. Co-infection did not influence the maximum liver enzyme level or the fibrosis progression throughout the study.
    Authors
    Crespo, M; Navarro, J; Moreno, S; Sanz, J; Márquez, M; Zamora, J; Ocampo, A; Iribaren, JA; Rivero, A; Llibre, JM
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/13952
    Collections
    • Centre for Primary Care and Public Health [1575]
    Language
    eng spa
    Copyright statements
    © 2016 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved

    Related items

    Showing items related by title, author, creator and subject.

    • SCREENING FOR HEPATITIS C Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified 

      Foster, GR; Gore, C; Hudson, M; Moss, P; Ustianowski, A; Ryder, S; Bhagani, S (2015-02-24)
    • Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure 

      Salpini, R; D'Anna, S; Benedetti, L; Piermatteo, L; Gill, U; Svicher, V; Kennedy, PTF (2022-09-02)
    • High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B 

      Hansi, NK; Gill, US; Banerjee, A; Surendraraj, N; Patel, C; Naik, S; Foster, GR; Kennedy, PT (2014)
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.